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Simportance of the serum LOX-1 levels in the diagnosis and assessment of left
ventricular systolic heart failure and its relationship with serum pro-BNP.
Methods: Fifty-ﬁve patients with a diagnosis of systolic heart failure and 25 patients
without systolic heart failure were enrolled in this study. The study took place in the
department of cardiology at Uludag University School of Medicine between October
2011 and April 2012. Echocardiography was performed in all cases. Serum C-reactive
protein, pro-BNP and LOX-1 levels were studied.
Results: Serum LOX-1 and pro-BNP levels were signiﬁcantly higher in the heart
failure group and showed negative correlations with left ventricular ejection fraction.
However, there was no signiﬁcant correlation between serum LOX-1 and pro-BNP
levels. In addition, LOX-1 level in patients with ischemic cardiomyopathy was
signiﬁcantly higher than the patients with dilated cardiomyopathy. ROC analysis was
done for the studied sample of serum LOX-1, the ‘cut off’ level was determined as
1.31 ng/ml for LOX-1 giving a sensitivity of 56.3% and speciﬁcity of 96% for the
diagnosis of the systolic heart failure.
Conclusion: Our study demonstrates the utility of the serum LOX-1 levels in the
diagnosis of left ventricular systolic heart failure. LOX-1 may have an important place
in the diagnosis of heart failure, especially when the etiology is ischemic cardiomy-
opathy. Further prospective studies with larger sample sizes are needed to better
understand the exact role of LOX-1 in the diagnosis and assessment of heart failure.Table 1. The demographic and baseline clinical characteristics of the heart
failure and control groups
Heart failure group Control group p value
Age (years) 64 (22-83) 62 (50-78) 0.306
Hypertension (n, %) 30 (54.5%) 14 (56%) 1.000
Hyperlipidemia (n, %) 21 (38.2%) 14 (56%) 0.323
Smoking (n, %) 9 (16.4%) 2 (8%) 0.511
Left ventricular ejection fraction 27 (18-44) 65 (54-73) <0.001
Table 2. Laboratory data of the heart failure and control groups
Heart failure Control group value
Blood glucose (mg/dl) 91.417.2 90.912 0.882
Urea (mg/dl) 45 (21-99) 32 (19-44) <0.001
Creatinine (mg/dl) 0.9 (0.6-1.4) 0.7 (0.6-1.1) <0.001
GFR (ml/min/1.73 m2) 84 (44-148) 96 (65-144) 0.012
Sodium (mg/dl) 137 (125-144) 141(138-144) <0.001
Potassium (mg/dl) 4.30.51 4.4 0.44 0.602
Calcium (mg/dl) 9.0 (6.3-10.5) 9.5 (8.6-11.2) 0.001
Hemoglobin (g/dl) 12.71.97 14.3 0.86 <0.001
LOX-1 (ng/ml) 1.46 (0.56-4.09) 0.99 (0.58-1.7) <0.001
Pro-BNP (mg/ml) 3560 (211-20806) 97 (18-184) <0.001
CRP (mg/L) 0.8 (0.3-5.5) 0.33 (0-0.5) <0.001
GFR: Glomerular ﬁltration rate, CRP: C-reactive protein, LOX-1: Lectin like oxidized LDL
receptor-1, BNP: Brain natriuretic peptide
Table 3. Comparison of patients according to the etiology of heart failure
DCMP (n¼24) ICMP (n¼ 31) p value
Ejection fraction (%) 25 (18-44) 30 (19-44) 0.165
LOX-1 (ng/ml) 1.16 (0.56-2.84) 1.65 (0.64-4.09) 0.027
Pro-BNP (mg/ml) 2806 (211-17277) 5200 (248-20806) 0.044
CRP (mg/L) 0.52 (0.3-3.5) 1.3 (0.3-5.54) 0.058
CRP: C-reactive protein, LOX-1: Lectin like oxidized LDL receptor-1, BNP: Brain natriuretic
peptide, DCMP: dilated cardiomyopathy, ICMP: ischemic cardiomyopathy
Table 1
Age (years) 63.2  12.7
Male gender 168
EF (%) 26.5  6.4
Hypertension (%) 62.3
Diabetes mellitus (%) 28.9
Smoking (%) 17.3
Ischemic cardiomyopathy (%) 82.7
WBC (X1,000/ml) 12.6  4.9
Neutrophil (%) 79.3  13.5
Lymphocyte (%) 17.1  7.2
Neutrophil-to-lymphocyte ratio 6.5  4.7
Baseline characteristics and hematological variables
Table 2
Variables Group 1 Group 2 p
D WBC 0.5  2.2 1.1  5.1 0.216
D Neutrophil 3.3  7.8 - 1.1  7.7 0.001
D Lymphocyte -1.4  6.1 1.1  5.4 0.012
D NLR 1.1  3.7 -2.7  11.6 <0.001
Comparison of changes in hematological variables of the patients who survived (group 1) and
died (group 2)after levosimendan therapyOP-167
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Aim: The aim of the study was to investigate the effect of levosimendan infusion on
hematological variables in patients with acute heart failure. Also, predictive value of
these variables over in hospital mortality evaluated.C74 JACC VMethods: Two hundred and nineteen patients (168 male, 51 female, mean age
63.212.7 years) with acute exerbation of advanced heart failure (ejection fraction
35%) were included in this study. Levosimendan was initiated as a bolus of 6 mg/kg
followed by a continuous infusion of 0,1 mg/kg/min for 24 hours. Changes of
hematological variables between admission and on third day after levosimendan
infusion were evaluated. Categorical variables were expressed as frequencies and
percentages. Continuous variables were compared using analysis of variance and
Kruskal-Wallis tests for those with normal and skewed distributions, respectively.
Chi-square tests were used to compare categorical variables. Univariate and multi-
variate Cox regression models were used to evaluate the independent association of
different hematological variables with in-hospital mortality.
Results: Table 1 demonstrated the baseline demographical and laboratory
characteristics of the patients. After levosimendan therapy, signiﬁcant decrease in
WBC and neutrophil counts and increase in lymphocyte count. As a result,
neutrophil to lymphocyte ratio (NLR) decreased. Compared to patients that
survived, in patients who died during in-hospital stay, these hematological changes
not occurred (Table 2). D NLR detected as independent predictor of in hospital
mortality when other hematological variables associated with mortality analysed in
the multivariate logistic regression analysis (R2¼0.094, p¼0.003).
Conclusion: Our study showed that levosimendan treatment is associated with
signiﬁcant changes in hematological variables in patients with acute exacerbation of
advanced heart failure. The difference between baseline and post-treatment NLR is
independent predictor of in hospital mortality.OP-168
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Introduction: Disease management programs for the treatment of patients with heart
failure (HF) have been advocated by society guidelines in order to improve patient
compliance and decrease hospitalizations. However, there are several different HF
management programs; most of them are costly and are not feasible to use in various
geographic areas. The aim of this study was to assess the efﬁcacy and feasibility of
a cardiologist lead enhanced HF education at the time of hospital discharge with a 6
month phone follow- up program in chronic HF patients.
Methods: The Hit Point trial was a multicenter; randomized, controlled trial of
enhanced HF education with a 6 month phone follow-up program (EHFP) vs routine
care (RC) in patients who carried the diagnosis of HF secondary to systolic
dysfunction, had been hospitalized for HF within six months of randomization, and
had symptoms despite optimal medical therapy. Education included information on
the adherence to treatment, symptoms recognition, diet and ﬂuid intake, weight
monitoring, activity, exercise training and when to contact cardiologist. Patients wereol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORALS
